Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Assets (2023 - 2025)

Historic Assets for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $16.5 million.

  • Mangoceuticals' Assets rose 1176.15% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year increase of 1176.15%. This contributed to the annual value of $15.4 million for FY2024, which is 136275.35% up from last year.
  • Per Mangoceuticals' latest filing, its Assets stood at $16.5 million for Q3 2025, which was up 1176.15% from $20.8 million recorded in Q2 2025.
  • Mangoceuticals' Assets' 5-year high stood at $21.8 million during Q1 2025, with a 5-year trough of $301447.0 in Q1 2024.
  • Over the past 3 years, Mangoceuticals' median Assets value was $15.0 million (recorded in 2024), while the average stood at $11.1 million.
  • The largest annual percentage gain for Mangoceuticals' Assets in the last 5 years was 711647.82% (2025), contrasted with its biggest fall of 1176.15% (2025).
  • Mangoceuticals' Assets (Quarter) stood at $1.1 million in 2023, then soared by 1362.75% to $15.4 million in 2024, then grew by 7.56% to $16.5 million in 2025.
  • Its Assets was $16.5 million in Q3 2025, compared to $20.8 million in Q2 2025 and $21.8 million in Q1 2025.